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Background: The Biomarker-integrated Approaches of Targeted 
Therapy for Lung Cancer Elimination trial1 prospectively obtained 
serum and tumor core biopsies and randomized 255 chemorefractory 
non–small-cell lung cancer (NSCLC) patients into four phase II trials: 
erlotinib, erlotinib-bexarotene, vandetanib, or sorafenib. Herein, we 
report the clinical and biomarker results of the phase II vandetanib trial.
Results: Fifty-four patients received vandetanib. The 8-week disease 
control rate was 33%, median progression-free survival (PFS) 1.81 
months, and median overall survival (OS) 6.5 months. No demographic 
subgroups had PFS or OS benefit. Eight patients with EGFR mutations 
had a trend for higher 8-week disease control rate (63% versus 31%; p = 
0.12) but worse OS (5.9 months versus 9 months; p = 0.8). Patients with 
EGFR gene amplification (n = 6) had a worse OS (3.9 months versus 
9.5 months; p = 0.04). KRAS mutation patients (3.9 months versus 9.5 
months; p = 0.23) also had a worse OS. For the serum biomarker analy-
sis, patients with below the median serum expression of interleukin 9c 
(p = 0.019) and eotaxin (p = 0.007) had a shorter PFS. A trend toward 
a shorter PFS was also seen in patients with higher than the median 
neutrophil gelatinase-associated lipocalin (p = 0.079) and lower than 
the median TNF-related apoptosis-inducing ligand (p = 0.087).
Conclusion: Our trial results are largely consistent with the litera-
ture in unselected pretreated NSCLC patients. Although vandetanib 
improved median PFS in EGFR mutation patients with epidermal 
growth factor receptor tyrosine kinase inhibitor–resistance compared 
with EGFR wild-type, there was no OS advantage. Although van-
detanib is no longer in development in NSCLC, identification of a 
molecular phenotype that responds to dual epidermal growth factor 
receptor and vascular endothelial growth factor receptor inhibition 
would contribute to the field.
Key Words: Vandetanib, Non–small-cell lung cancer, EGFR muta-
tion, EGFR gene amplification.
(J Thorac Oncol. 2013;8: 658-661)
The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial1 conducted 
at M.D. Anderson Cancer Center (Houston, Texas) random-
ized (using 1 of 2 algorithms) 255 chemorefractory non–
small-cell lung cancer (NSCLC) patients into four separate 
phase II targeted therapy trials: erlotinib (OSIP/Genentech, 
San Francisco, CA), erlotinib plus bexarotene (Eisai, Tokyo, 
Japan), vandetanib (AstraZeneca, London, UK), or sorafenib 
(Bayer/Onyx, San Francisco, CA). In this trial, core tumor 
biopsies were prospectively obtained for biomarker analysis 
of 11 prespecified markers. Herein, we report the clinical and 
biomarker results of the phase II vandetanib trial. Vandetanib 
targets vascular endothelial growth factor receptor (VEGFR) 
and epidermal growth factor receptor (EGFR). The rationale 
for this trial was based on prior vandetanib salvage studies 
that demonstrated improved progression-free survival (PFS) 
but no overall survival (OS) benefit in NSCLC.2–5 Identifying 
the molecular phenotype or subgroup of patients that would 
benefit from vandetanib was a high priority, and it was hypoth-
esized that patients with EGFR tyrosine kinase inhibitor (TKI) 
resistance would benefit from vandetanib salvage therapy.
PATIENTS AND METHODS
BATTLE was a phase II trial that enrolled patients with 
chemorefractory NSCLC at M.D. Anderson Cancer Center, 
who had Eastern Cooperative Oncology Group (ECOG) 
performance status 0 to 2, tumors amenable to core biopsy, any 
line of prior therapy, and adequate organ function. Patients with 
stable treated brain metastases more than 4 weeks before were 
allowed on study. After molecular tumor biomarker evaluation, 
patients were randomized to oral therapy with erlotinib (150 mg 
daily), erlotinib (150 mg daily) plus bexarotene (400 mg/m2 
daily), vandetanib (300 mg daily), or sorafenib (400 mg twice 
daily). Radiographic assessment for response was obtained 
every 8 weeks. Adverse events were assessed by National 
Cancer Institute Common Toxicity Criteria v. 3.0. every 4 weeks 
while on therapy. Clinical outcomes evaluated included disease 
control rate (DCR = stable disease [SD] + partial response [PR] + 
complete response [CR]), response rate (PR + CR), PFS, OS, 
and toxicity. PFS was defined as time from randomization to 
disease progression or death without progression. PFS, OS, 
and response duration were estimated using Kaplan–Meier 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0805-0658
Clinical and Biomarker Outcomes of the Phase II 
Vandetanib Study from the BATTLE Trial
Anne S. Tsao, MD,* Suyu Liu, PhD,† J. Jack Lee, PhD,† Christine M. Alden, RN,* 
George R. Blumenschein, Jr., M.D,* Roy Herbst, MD, PhD,║ Suzanne E. Davis, MMS,§ Edward Kim, MD,* 
Scott Lippman, MD,* John Heymach, MD, PhD,* Hai Tran, PhD,* XiMing Tang, MD, PhD,*‡  
Ignacio Wistuba, MD,*‡ and Waun Ki Hong, MD*§ 
Departments of *Thoracic/Head & Neck Medical Oncology, †Biostatistics, 
‡Pathology, §Division of Cancer Medicine,The University of Texas M.D. 
Anderson Cancer Center Houston, Texas; and ║Yale Cancer Center, New 
Haven, Connecticut.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Anne S. Tsao, MD, Associate Professor, 
Department of Thoracic/Head & Neck Medical Oncology, 1515 Holcombe 
Blvd. Unit 432, Houston, TX 7030. E-mail: astsao@mdanderson.org
BRIEF REPORT
659Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 5, May 2013 Results of Phase II Vandetanib BATTLE Trial
method. Log-rank tests were used to conduct univariate 
analyses, and Cox proportional hazards models were used to 
adjust for multivariables. The molecular biomarkers evaluated 
include: EGFR mutation, EGFR gene amplification, EGFR 
high polysomy, KRAS mutation, BRAF mutation, VEGF 
immunohistochemistry (IHC), VEGFR2 IHC, retinoid × 
receptor α cytoplasmic and nucleic IHC, retinoid × receptor β 
cytoplasmic and nucleic IHC, retinoid × receptor γ cytoplasmic 
IHC, cyclin D1 IHC, cyclin D1 gene amplification. The IHC 
biomarkers were assessed as continuous values and also as 
discrete markers with the cutoff detailed in the original article.1 
The other biomarkers were all assessed as discrete biomarkers. 
Previously, we had identified that levels of circulating protein 
biomarkers may be associated with outcome in patients treated 
with vandetanib and other VEGFR inhibitors.6–8 In this study, 
we assessed 58 factors in serum from patients before treatment, 
using multiplex bead analysis.6,7,9
RESULTS
Of the 255 patients randomized in the BATTLE-1 clini-
cal trial, 54 patients received vandetanib. Patient characteris-
tics are included in Table 1. Average overall compliance was 
high at 99%, with only two patients (4%) requiring a dose 
reduction. Table 2 summarizes the adverse events encountered 
during the trial. The main toxicities experienced on the trial 
(any grade) included fatigue, diarrhea, elevated alkaline phos-
phatase, elevated liver function tests, hypertension, and rash. 
There was an 11% rate of grade 3 to 5 nonhematologic toxic-
ity. One patient had a possible treatment-related death after 
developing a pulmonary embolus, and one squamous cell car-
cinoma patient experienced grade two hemoptysis; there were 
no other incidences of bleeding.
The DCR at 8 weeks for all patients treated with vande-
tanib was 33%. With a median follow-up time of 7.42 months, 
the median PFS was 1.81 months and 1-year PFS rate was 5%. 
After a median follow-up time of 17.5 months, the median OS 
was 6.5 months with a 1-year OS rate of 26%. No demographic 
subgroups had a PFS or OS benefit; patients with ECOG per-
formance status 2 had a worse OS (hazard ratio [HR] 2.42; 
p = 0.02) compared with patients with ECOG 0 to 1.
Eighteen patients (11 grade 2 and 7 grade 3) experienced 
hypertension and had a higher 8-week DCR (64.71% versus 
17.14%; p = 0.0006), better PFS (HR = 0.31; p = 0.0006), and 
better OS (HR = 0.42; p = 0.0096). Seventeen patients devel-
oped a rash (11 grade 1, 5 grade 2, and 1 grade 3) and had an 
improved 8-week DCR (52.94% versus 22.86%; p = 0.03), 
better PFS (HR = 0.45; p = 0.01), and improved OS though 
it did not reach statistical significance (HR = 0.62; p = 0.14).
In the tissue biomarker analysis, when the angiogenesis 
biomarkers were analyzed as a continuous variable, higher 
expression of VEGFR2 IHC correlated with an improved DCR 
(p = 0.05). However, this was not predictive of a PFS benefit. 
A marginally significant trend associated higher VEGFR2 IHC 
expression (HR = 0.69 [95% CI: 0.47, 1.02] for every 100 units 
increase of VEGFR2 IHC; p = 0.06) with an improved OS.
TABLE 1.  Patient Characteristics
Characteristic N Patients (%)
Age (yr) <50 11 (20)
 Mean = 61 51–60 15 (28)
 Range, 34–80 61–70 19 (35)
>70 9 (17)
Sex
Female 29 (54)
Male 25 (46)
Ethnicity
White 41 (76)
Hispanic 7 (13)
African American 2 (4)
Asian 4 (7)
Smoker
Current 5 (9)
Former 31 (57)
Never 18 (33)
Histology
Adenocarcinoma 35 (65)
Squamous cell 7 (13)
Other 12 (22)
Prior therapy Erlotinib 45 (83)
Median 2 1 Chemotherapy 21 (39)
Range 1–6 2 Chemotherapy 17 (31)
3 Chemotherapy 7 (13)
4 Chemotherapy 6 (11)
5 Chemotherapy 2 (4)
6 Chemotherapy 1 (2)
ECOG performance status
0 9 (17)
1 36 (67)
2 9 (17)
ECOG, Eastern Cooperative Oncology Group.
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FIGURE 1.  Non–small-cell lung cancer patients with EGFR 
gene amplification have a worse overall survival (p = 0.04) 
when treated with vandetanib.
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Eight patients with EGFR mutations (Table 3) 
trended with higher 8-week DCR (63% versus 31%; p = 
0.12) but worse OS (5.9 months versus 9 months; p = 0.8) 
compared with EGFR wild-type patients. Seven of these 
eight EGFR-mutated patients were resistant to erlotinib 
and had two or more lines of prior chemotherapy. Patients 
with EGFR gene amplification (n = 6) had a worse OS (3.9 
months versus 9.5 months; p = 0.04)(Fig. 1). KRAS muta-
tion patients (3.9 months versus 9.5 months; p = 0.23) also 
had a worse OS.
For the serum biomarker analysis, patients with below 
the median serum expression of interleukin 9c (p = 0.019) 
and eotaxin (p = 0.007) had a shorter PFS. A trend toward 
a shorter PFS was also seen in patients with higher than the 
median neutrophil gelatinase-associated lipocalin (p = 0.079) 
and lower than the median TNF-related apoptosis-inducing 
ligand (p = 0.087).
DISCUSSION
The clinical results of our vandetanib study were largely 
consistent with the literature compared with prior published 
salvage vandetanib monotherapy arm randomized trials (Table 
4).2,10,11 There were no new safety signals observed and the 
prognostic correlation of rash and hypertension development 
with improved clinical outcomes was noted. It was evident 
that certain NSCLC patients benefit from vandetanib but are 
yet to be defined molecularly.12
Whether predictive biomarkers will ultimately be iden-
tified in serum or tissue remains unclear. Prior reports have 
suggested that lower baseline plasma VEGF levels seem pre-
dictive of clinical benefit from vandetanib relative to erlo-
tinib;6,12 and other trials have shown distinct cytokine and 
angiogenic factor modulation in patients treated with either 
vandetanib or chemotherapy.9 In our trial, lower median 
serum expression of interleukin 9 and eotaxin correlated with 
a worse PFS. However, the significance of this will require 
additional study.
In our tumor tissue studies, we were unable to iden-
tify a reliable predictive biomarker to vandetanib treatment. 
However, our patients with increased EGFR gene copy number 
experienced a worse OS. A similar finding has been reported 
in a Japanese study, where one of 27 Japanese patients treated 
with vandetanib had increased EGFR gene copy number and 
had progression of disease as their best response.12 The mech-
anism by which this occurs remains unknown and stands in 
contrast to other EGFR TKI trials with erlotinib where EGFR 
gene copy number was predictive of a clinical benefit to EGFR 
TKI.13,14
When our trial was designed from preclinical studies,15 
it was hypothesized that patients with EGFR TKI resistance 
(including T790M) would benefit from vandetanib salvage. 
In our trial, the eight EGFR-mutated patients had a higher 
median PFS (3.2 months versus 1.8 months) compared with 
TABLE 3.  Patient EGFR Mutations and Associated Clinical Outcome
Patient
EGFR 
Exon 
Mutation Altered Nucleotide Altered Amino Acid
Patient 
History of 
Resistance to 
EGFR TKI
Best 
Response
8-Week 
DCR
PFS 
(mo)
OS 
(mo)
1 E21 CTG858CGG Leu858Arg Yes SD Yes 6.1 20.4
2 E21 CTG858CGG Leu858Arg Yes SD Yes 5.7 38.5
3 E19/E20 del15bp (746E-750A) /ACG790ATG del746Glu750Ala/Thr790Met Yes SD Yes 3.8 5.5
4 E19 del15bp (746E-750A) del746Glu-750Ala Yes PD No 0.9 1.2
5 E19/E20 del15bp (746E-750A) /TGC797TAC del746Glu-750Ala/Cys797Tyr No PD No 0.9 1.0
6 E20 CAC773CGC His773Arg Yes PR Yes 7.4 7.4
7 E20/E21 ACG790ATG/CTG858CGG Thr790Met/Leu858Arg Yes PD No 1.9 4.1
8 E20/E21 GTC802ATC/AAG852AGG Val802Ile/Lys852Arg Yes SD Yes 2.6 6.3
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; DCR, disease control rate; PFS, progression-free survival; OS, overall survival.
TABLE 2.  Summary of Adverse Events (>10% in All Patients, 
Based on 54 pts)
Total
(N = 54)
Event
All Grade Grade 3, 4, or 5
n (%) n (%)
Abnormal electrolytes 25 46.3 3 5.6
Constitutional symptoms 24 44.4 3 5.6
Diarrhea 23 42.6 0 0
Elevated Alk phos 21 38.9 2 3.7
Abnormal liver enzymes 19 35.2 2 3.7
Hypertension 18 33.3 7 13
Rash 17 31.5 1 1.9
Anorexia 15 27.8 2 3.7
Hyperglycemia 15 27.8 0 0
Pain 15 27.8 1 1.9
Proteinuria 14 25.9 0 0
GI complaint 13 24.1 1 1.9
Infection 13 24.1 2 3.7
Renal insufficiency 12 22.2 0 0
Anemia 11 20.4 0 0
Pulmonary 11 20.4 3 5.6
Bleed 10 18.5 0 0
Hypoalbuminemia 7 13 1 1.9
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EGFR wild-type patients; but, unlike other studies,11 in our 
study the mutated patients had a trend toward a worse OS 
with vandetanib. This finding may be because the majority of 
our EGFR-mutated patients had prior EGFR TKI resistance 
and two had the T790M resistance mutation. Also, patients 
with less common EGFR mutations did not seem to gain any 
significant OS benefit from vandetanib.
In conclusion, our phase II vandetanib was consistent 
with prior reported clinical outcomes in unselected pretreated 
NSCLC patients. Although vandetanib slightly improved 
median PFS in patients with EGFR mutations with demon-
strated EGFR TKI resistance (with or without T790M) com-
pared with EGFR wild-type patients, no OS advantage was 
seen. Although vandetanib is no longer in development in 
NSCLC, identification of the patient molecular phenotype that 
responds to dual EGFR and VEGFR inhibition would contrib-
ute to the field.
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TABLE 4.  Summary of Selected Phase II/Phase III Trials 
Containing Vandetanib Monotherapy Arms and Clinical 
Outcome
Trials with  
Vandetanib 
Monotherapy  
Arms
Trial  
Phase
Median  
PFS (mo)
HR 
p
Median 
OS (mo)
HR 
p 
Current trial II 1.81 N/A 6.5 N/A
 EGFR mutation 3.2 5.9
ZEPHYR  
Lee et al.11
III
 Vandetanib arm 1.9 0.63 8.5 0.95
 Placebo arm 1.8 p < 0.001 7.8 p = 0.527
Natale et al.2 III
 Vandetanib arm 2.6 0.98 6.9 1.01
 Erlotinib arm 2.0 p = 0.72 7.8 p = 0.83
Natale et al.10 II
 Vandetanib arm 2.75a 0.69a 6.1 1.19
 Gefitinib arm 2.03a p = 0.025 7.4 p = 0.34
aResults reported are before cross-over. 
PFS, progression-free survival; HR, hazard ratio; OS, overall survival; N/A, 
not applicable; ZEPHYR, International, Randomised, Double-Blind Parallel Group, 
Multicenter Study to Assess the Efficacy of ZD6474 (ZACTIMA) plus Best Supportive 
Care Versus Placebo Plus Best Supportive Care in Patients With Locally Advanced or 
Metastatic (Stage IIIB-IV) Non-Small Cell Lung cancer (NSCLC) after Prior Therapy 
with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI).
